+44 20 8123 2220
info@marketpublishers.com

Gastroesophageal Junction Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

https://marketpublishers.com/r/G878001D74CDEN.html
Date: May 2024
Pages: 128
Price: US$ 6,499.00 (Single User License)
ID: G878001D74CDEN

Abstracts

The 7 major gastroesophageal junction adenocarcinoma markets are expected to exhibit a CAGR of 13.82% during 2024-2034.

The gastroesophageal junction adenocarcinoma market has been comprehensively analyzed in IMARC's new report titled "Gastroesophageal Junction Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Gastroesophageal junction adenocarcinoma is a type of cancer arising from the glandular cells that line the inner surface of the esophagus. The symptoms of this ailment can vary depending on the stage and location of the tumor. Some common indications associated with the illness include difficulty swallowing, unintended weight loss, chest pain or discomfort, indigestion, worsening heartburn, black or tarry stools, vomiting, nausea, fatigue, pale skin, coughing, hoarseness, shortness of breath, etc. These symptoms may gradually develop or become more pronounced as the tumor grows and affects the function of the digestive system. The diagnosis of gastroesophageal junction adenocarcinoma typically involves a combination of the patient's clinical features, medical history, and physical examination. Various imaging tests, such as upper endoscopic ultrasound, X-ray, positron emission tomography (PET) scan, etc., are also utilized to evaluate the extent and spread of cancer. The healthcare provider may further conduct molecular testing of tumor tissue to identify specific genetic mutations or alterations associated with the condition. In some cases, an imaging-guided biopsy is recommended to determine the presence of cancer and confirm its type and grade.

The increasing cases of chronic acid reflux, which causes long-lasting inflammation and damage to the lining of the esophagus, are primarily driving the gastroesophageal

+44 20 8123 2220
info@marketpublishers.com

junction adenocarcinoma market. In addition to this, the rising prevalence of mutations in tumor suppressor genes that help to regulate cell division and prevent the formation of cancerous cells is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, such as trastuzumab, ramucirumab, pembrolizumab, etc., to treat the ailment is further bolstering the market growth. These agents inhibit specific proteins or signaling pathways involved in disease progression, thereby improving the quality of life for patients. Apart from this, the inflating application of endoscopic mucosal resection procedures, since they can remove abnormal or cancerous tissue in the gastrointestinal tract while preserving the surrounding healthy cells, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cryotherapy owing to its various advantages, like smaller incisions, reduced risk of complications, faster recovery times, etc., is expected to drive the gastroesophageal junction adenocarcinoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the gastroesophageal junction adenocarcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gastroesophageal junction adenocarcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gastroesophageal junction adenocarcinoma market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany

+44 20 8123 2220
info@marketpublishers.com

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the gastroesophageal junction adenocarcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the gastroesophageal junction adenocarcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current gastroesophageal junction adenocarcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

+44 20 8123 2220
info@marketpublishers.com

Key Questions Answered in this Report:
Market Insights

How has the gastroesophageal junction adenocarcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the gastroesophageal junction adenocarcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the gastroesophageal junction adenocarcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of gastroesophageal junction adenocarcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of gastroesophageal junction adenocarcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of gastroesophageal junction adenocarcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with gastroesophageal junction adenocarcinoma across the seven major markets?
What is the size of the gastroesophageal junction adenocarcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of gastroesophageal junction adenocarcinoma?
What will be the growth rate of patients across the seven major markets?

Gastroesophageal Junction Adenocarcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?

+44 20 8123 2220
info@marketpublishers.com

How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for gastroesophageal junction adenocarcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gastroesophageal junction adenocarcinoma market?
What are the key regulatory events related to the gastroesophageal junction adenocarcinoma market?
What is the structure of clinical trial landscape by status related to the gastroesophageal junction adenocarcinoma market?
What is the structure of clinical trial landscape by phase related to the gastroesophageal junction adenocarcinoma market?
What is the structure of clinical trial landscape by route of administration related to the gastroesophageal junction adenocarcinoma market?

+44 20 8123 2220
info@marketpublishers.com

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION

+44 20 8123 2220
info@marketpublishers.com

7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)

+44 20 8123 2220
info@marketpublishers.com

7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - UNMET NEEDS

10 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - KEY ENDPOINTS OF TREATMENT

11 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - MARKETED PRODUCTS

11.1 List of Gastroesophageal Junction Adenocarcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Enhertu (Trastuzumab deruxtecan) - AstraZeneca/Daiichi Sankyo
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status

+44 20 8123 2220
info@marketpublishers.com

11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Cyramza (Ramucirumab) - Eli Lilly and Company
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Taxotere (Docetaxel) - Sanofi Aventis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Lonsurf (Tipiracil/trifluridine) - Taiho Pharmaceutical
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Herceptin (Trastuzumab) - Genentech
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - PIPELINE DRUGS

12.1 List of Gastroesophageal Junction Adenocarcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Evorpacept (ALX148) - ALX Oncology
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

+44 20 8123 2220
info@marketpublishers.com

12.1.2 Tucatinib - Seagen
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Bemarituzumab - Amgen
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 DKN-01 - Leap Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 TORL-2-307-MAB - TORL Biotherapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - MARKET SCENARIO

+44 20 8123 2220
info@marketpublishers.com

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Gastroesophageal Junction Adenocarcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Gastroesophageal Junction Adenocarcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Gastroesophageal Junction Adenocarcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Gastroesophageal Junction Adenocarcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Gastroesophageal Junction Adenocarcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Gastroesophageal Junction Adenocarcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Gastroesophageal Junction Adenocarcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Gastroesophageal Junction Adenocarcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Gastroesophageal Junction Adenocarcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Gastroesophageal Junction Adenocarcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapiesn (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Gastroesophageal Junction Adenocarcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Gastroesophageal Junction Adenocarcinoma - Market Size
15.6.1.1 Market Size (2018-2023)

+44 20 8123 2220
info@marketpublishers.com

15.6.1.2 Market Forecast (2024-2034)
15.6.2 Gastroesophageal Junction Adenocarcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Gastroesophageal Junction Adenocarcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Gastroesophageal Junction Adenocarcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Gastroesophageal Junction Adenocarcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Gastroesophageal Junction Adenocarcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Gastroesophageal Junction Adenocarcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Gastroesophageal Junction Adenocarcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Gastroesophageal Junction Adenocarcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Gastroesophageal Junction Adenocarcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Gastroesophageal Junction Adenocarcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies n(2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Gastroesophageal Junction Adenocarcinoma - Access and Reimbursement Overview

16 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA MARKET - SWOT ANALYSIS

+44 20 8123 2220
info@marketpublishers.com

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Gastroesophageal Junction Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: https://marketpublishers.com/r/G878001D74CDEN.html

Price: US$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G878001D74CDEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com